<p><strong>Pediatric Use</strong>: Difluprednate was evaluated in 0 to 3 years of age for the treatment of inflammation following cataract surgery. A similar safety profile was observed in pediatric patients comparing Difluprednate to Prednisolone Acetate ophthalmic suspension 1%.<br />
<br />
<strong>Geriatric Use</strong>: No overall differences in safety or effectiveness have been observed between elderly and younger patients</p>